Mergers and acquisitions

BMS will shed Otezla to push Celgene takeover through

Bristol-Myers Squibb has opted to divest big-selling psoriasis drug Otezla to smooth the passage of its $74 billion

BMS will shed Otezla to push Celgene takeover through

https://pharmaphorum.com/news/bms-will-shed-otezla-to-push-celgene-takeover-through/

Sanofi steals in to buy Ablynx for €3.9 billion

Sanofi has leapt in to buy Ablynx for €3.9 billion ($4.85bn) outbidding an offer from Novo Nordisk which

Sanofi steals in to buy Ablynx for €3.9 billion

https://pharmaphorum.com/news/sanofi-steals-buy-ablynx-e3-9-billion/

Novo Nordisk and Celgene lead January pharma M&A

Novo’s bid

Novo Nordisk and Celgene lead January pharma M&A

https://pharmaphorum.com/news/novo-nordisk-celgene-lead-january-pharma-ma/

Biotech and big pharma heading for a M&A filled 2018

After a relatively quiet 12 months for mergers and acquisitions in 2017, this year is expected to produce

Biotech and big pharma heading for a M&A filled 2018

https://pharmaphorum.com/news/biotech-big-pharma-heading-ma-filled-2018/

Takeda to buy Ariad for $5.2bn

Pharma M&A could surge in 2017, says report

Takeda to buy Ariad for $5.2bn

https://pharmaphorum.com/news/takeda-buy-ariad-5-2bn/

Johnson & Johnson back in ‘exclusive’ talks to buy Actelion

Deal expected to be worth around $30 billion.

Johnson & Johnson back in ‘exclusive’ talks to buy Actelion

https://pharmaphorum.com/news/johnson-johnson-back-exclusive-talks-buy-actelion/

BIND accepts Pfizer bid following bankruptcy

Bid of $20 million may be enough to acquire all of BIND’s assets.

BIND accepts Pfizer bid following bankruptcy

https://pharmaphorum.com/news/bind-accepts-pfizer-stalking-horse-bid-following-motion-sell-assets/

Celgene’s new CEO weighs in to drug pricing debate

Celgene’s new CEO Mark Alles discusses pricing and M&A, criticises Valeant’s approach. Richard Staines reports. Richard Staines Celgene’s

Celgene’s new CEO weighs in to drug pricing debate

https://pharmaphorum.com/views-and-analysis/celgene-s-new-ceo-weighs-in-to-drug-pricing-debate/

Pharma news round-up: Pfizer-Allergan merger scrapped, Gilead to buy Nimbus Apollo, WHO diabetes campaign and more

A round-up of this week’s top pharma and healthcare news – plus reaction from social media. Marco Ricci

Pharma news round-up: Pfizer-Allergan merger scrapped, Gilead to buy Nimbus Apollo, WHO diabetes campaign and more

https://pharmaphorum.com/views-and-analysis/pharma-news-round-up-pfizer-allergan-merger-scrapped-gilead-to-buy-nimbus-apollo-who-diabetes-campaign-and-more/

1 2

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Search

Advanced Search

Trending

Mergers and acquisitions